NextCure Inc 2026年季度报告

(Mark One) For the quarterly period ended June 30, 2026 or NextCure, Inc. (Exact name of registrant as specified in its charter) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant:(1)has filed all reports required to be filed by Section13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter periodthat the registrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company” and “emerging growth company” in Rule12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☒Emerginggrowthcompany☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act).Yes☐No☒ As of July 31, 2026, the registrant had 4,577,359 shares of common stock, par value $0.001 per share, issued and outstanding. NextCure, Inc.Form 10-QFor the Quarter Ended June 30, 2026 TABLE OF CONTENTS PARTI. FINANCIAL INFORMATIONItem 1.Financial Statements 1Condensed Balance Sheets as of June 30, 2026 (unaudited) and December 31, 20251Unaudited Condensed Statements of Operations and Comprehensive Loss for the Three andSix Months Ended June 30, 2026 and 20252Unaudited Condensed Statements of Stockholders’ Equity for the Three and Six MonthsEnded June 30, 2026 and 20253Unaudited Condensed Statements of Cash Flows for the Six Months Ended June 30, 2026and 20254Notes to Unaudited Condensed Financial Statements5Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations18Item 3.Quantitative and Qualitative Disclosures about Market Risk30Item 4.Controls and Procedures30Part II. OTHER INFORMATIONItem 1.Legal Proceedings30Item 1A.Risk Factors31Item 2.Unregistered Sales of Equity Securities and Use of Proceeds32Item 3.Defaults Upon Senior Securities32Item 4.Mine Safety Disclosures32Item 5.Other Information32Item 6.Exhibits33SIGNATURES35 PART I. FINANCIAL INFORMATION NEXTCURE,INC.CONDENSED BALANCE SHEETS(in thousands, except share and per share amounts) June30,2026December31,(unaudited)2025AssetsCurrent assets:Cash and cash equivalents$15,260$25,982Marketable securities4,82815,836Prepaid expenses and other current assets2,1671,929Total current assets22,25543,747Property and equipment, net2833,273Right of use assets—2,617Other assets82546Total assets$22,620$50,183Liabilities and Stockholders’ EquityCurrent liabilities:Accounts payable$2,578$2,011Accrued liabilities and other liabilities3,8358,555Total current liabilities6,41310,566Lease liabilities, long term3,6034,148Other long-term liabilities455526Total liabilities10,47115,240Stockholders’ equity:Preferred stock, par value of $0.001 per share; 10,000,000 shares authorized at June30,2026 and December31,2025; No shares issued and outstanding at June 30,2026and December31,2025——Common stock, par value of $0.001 per share; 100,000,000 shares authorized at June30,2026 and December31,2025; 4,068,951and 3,505,621 shares issued andoutstanding at June 30,2026 and December31,2025, respectively44Additional paid-in capital472,816470,898Accumulated other comprehensive (loss) income(3)21Accumulated deficit(460,668)(435,980)Total stockholders’ equity12,14934,943Total liabilities and stockholders’ equity$22,620$50,183 NEXTCURE,INC.CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVELOSS(unaudited, in thousands, except share and per share amounts) NEXTCURE,INC.CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY(unaudited, in thousands, except share data) NEXTCURE,INC.CONDENSED STATEMENTS OF CASH FLOWS(unaudited, in thousands) The accompanying notes are an integral part of these unaudited condensed financial statements. 1. Nature of the Business Organization NextCure,Inc. (“NextCure” the “Company,” “we,” “us,” or “our”) was incorporated in Delawarein September2015 and is headquartered in Beltsville, Maryland. The Company is a clinical-stagebiopharmaceutical company that has focused on advancing innovative medicines that treat cancer patientsthat do not respond to, or that have disease progression on, current therapies, through the use of targetedtherapies including antibody-drug conjugates. The Company has focused on advancing therapies thatleverage o